Latest Kaiser Health News Stories
The latest technology makes managing Type 1 diabetes much easier. But managing insurance company rules for the supplies is a big obstacle for some patients.
Health experts say the little-used benefit represents a lost opportunity for older adults to improve their health — and for the program to save money by preventing costly complications from diabetes and chronic kidney disease.
People with diabetes say they’ve been waiting for years for better technology to manage their chronic condition. Tired of waiting, some tech-savvy, do-it-yourselfers are constructing their own devices using open-source programming instructions.
Patients with Type 2 diabetes are often steered toward medicine or insulin treatment. But with additional support, it’s possible to use diet and exercise to control blood sugar. The rising price of insulin drives patients to lower their dependence on the medicine.
KHN, in collaboration with PBS NewsHour, reports on the skyrocketing cost of insulin — and the trend’s deadly consequences. The price in the U.S. nearly doubled from 2012 to 2016, prompting some patients and activists to travel to Canada, where insulin can be 90% cheaper.
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
In California, people who are black or Latino are more than twice as likely as whites to undergo amputations related to diabetes, a Kaiser Health News analysis found. The pattern is not unique to California.
An estimated 1.25 million Americans have Type 1 diabetes and cannot live without insulin. Sen. Kamala Harris’ claim that 1 in 4 diabetes patients cannot afford their insulin is a shockingly high number, so we decided to dig into the sparse data.
The Adelanto ICE Processing Center houses nearly 2,000 people in California. Federal, state and watchdog reviews say the Florida-based firm that runs the facility fails to provide adequate health care.
During Wednesday’s House subcommittee hearing on insulin price hikes, drug makers and benefits managers pointed fingers at each other for the last decade’s 300% price increase, frustrating congressional representatives.
Only by the bizarre logic of the U.S. pharmaceutical industry does this drug count as any kind of generic.
Eli Lilly released a half-price generic version of its own short-acting insulin. At $137.35 per vial, the generic insulin is priced at about the same level as Humalog was in 2012.
Doctors and patients say they’re compelled to use off-label meds as research goes unfunded.
For one patient, a three-month supply of insulin is $3,700 in the U.S. versus $600 in Mexico. But is it legal?
Sen. Mike Enzi said he knew of a foundation that would import insulin for patients, but it doesn’t appear to exist.
Patients are often forced into using brand names because drug formularies favor them over cheaper competitors.
Democratic governors and mayors are unveiling new ideas to control costs and expand coverage. The federal government shutdown has spared most health agencies, but not all. And learn the latest on that lawsuit out of Texas, which is threatening the Affordable Care Act once again. Margot Sanger-Katz of The New York Times, Anna Edney of Bloomberg News and Rebecca Adams of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and, for “extra credit,” provide their favorite health policy stories of the week. Rovner also interviews KHN’s Jordan Rau about the latest “Bill of the Month.”
The price of insulin keeps going up. For people with Type 1 diabetes, high prices can be a life-or-death issue. Now a grass-roots movement is pushing for change.
Insurance companies profit from government contracts but are subject to little oversight of how they spend the money or care for patients. The expansion of Medicaid under the Affordable Care Act has only exacerbated the problem.
A DaVita subsidiary will pay $270 million over allegations that it cheated the federal government for years.